Abstract

Present day vaccines have a key role in influenza prophylaxis. Besides, there is a wide spectrum of pharmaceutics: antigrippine I, II, III, amantidin, remantadin, arbidol, laferon, etc. Anti-influenza vaccines and pharmaceutics mentioned above might cause side effects of blood circulating system (thrombocytopenia), immune system (allergic reactions), nervous system (frequent headaches, and less frequently cramps, encephalomyelitis, neuritis, Guillain-Barre syndrome), vascular system (vasculitis with acute damages of renal function).A new generation of antiviral remedies in the form of neuraminidase (zanamivir and oseltamivir) have appeared. They are free of the main drawbacks typical for vaccines and pharmaceutics of amantadin type and cause less resistance in viruses. Domestic scientists used the effect of influenza virus hemaglutine splitting by trypsin-like proteinase of respiratory tract cells of epithelium at two subunits (hemaagglutinin-1 and hemaagglutinin-2) have isolated inhibitor of trypsine-like proteinases which arrested development of influenza in white mice. Now they are searching biological material for isolation of trypsine-like proteinases as anti-virus remedy for a human.

Keywords: Influenza A Virus; Vaccines; Proteinase Ingibitors; Drags

References

1. Daniel Lavanchg. Influenza. Information and news in the field of influenza studies”. Bulletin. "Problems to be solved in the 21st century. European Working Group on Influenza Studies 10 (1999): 3-11.
2. Bobilova OO., et al. “The problem of infectious diseases remains an urgent problem of the health care system and the state”. Modern Infections 1 (2001): 4-10.
3. Mironenko AP and Mukhopad VO. “Strategies and stages of influenza control”. Infectious Diseases 2 (2001): 55-58.
4. Karpukhin GI. “Influenza”. SPb: Hippocrates (2001): 259.
5. Moskalyuk VD. “(Chernivtsi) Laferon in the complex treatment of patients with influenza A”. Infectious Diseases 1 (2001): 32-34.
6. Kiselev OI. “Influenza and other viral respiratory infections: epidemiology, prophilaxis, diagnostics and therapy”. Borghes (2003): 244.
7. Robertson J., et al. “High grow reassortant influenza vaccine virus: new appoaches to their control”. Biologicals 20 (1992): 213-220.
8. Hadzhiolova T and Kotseva R. “Specific and nonspecific factors of protection against influenza”. Modern Medicine5. (2005): 35-42.
9. Gendon Yu Z. “Strategy for combating influenza with vaccines”. Vaccine Prevention News 5 (1999): 3.
10. Gendon YuZ. “Live cold-adapted reassortant influenza vaccines”. Vopr Virusol 3 (2001): 5-12.
11. Gendon YuZ. “Cultural influenza vaccines”. Vopr Virusol 6 (2002): 4-11.
12. Elshina GA., et al. “Evaluation of the effectiveness of influenza trivalent vaccine "Grippol"”. Journal of Microbiology 3 (1998): 40-43.
13. Slepushkin AN. “WHO World Program for Epidemiological Surveillance and Influenza Control”. Vopr Virusol 1 (2003): 46-48.
14. Shevchenko ES., et al. “The spectrum of sensitivity to rimantadine of group A viruses circulating in the epidemic seasons of 2002-2004”. Вопр. Virus 5 (2005): 32-35.
15. Lviv DK., et al. “In vitro action of antiviral drugs on the reproduction of highly pathogenic strains of influenza A / H5N1 virus, which caused an epizootic among poultry in the summer of 2005”. Vopr Virusol 2 (2006): 20-25.
16. Fedyakina IT., et al. “Action of official antiviral drugs on reproduction of a virus of birds A / 215 isolated in Russia”. Vopr Virusol 4 (2006): 35-37.
17. Kozko VM., et al. “Efficacy of the drug arbidol - mens in the prevention and treatment of patients with influenza and SARS”. Infectious Diseases 1 (2004): 35-37.
18. Leneva IA., et al. “Sensitivity of different strains of the virus to arbidol. Study of the effect of arbidol on the reproduction of influenza A virus in combination with various antiviral drugs”. Therapist Archive 8 (2005): 84-88.
19. Gendon YuZ. “Advantages and disadvantages of inactivated and live influenza vaccine”. Vopr Virusol 4 (2004): 4-12.
20. Burtseva EI., et al. “Comparative study of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly”. Journal of Microbiology 5 (2000): 40-45.
21. Barantseva IB and Naikhin AN. “Humoral and local immune response to influenza vaccines in the elderly and young”. Vopr Virusol 2 (2003): 32-36.
22. Li Yong., et al. “Protective effect of specific antibodies of serum of patients recovering from SARS”. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue7 (2004): 409-411.
23. Kramarev SO. “Gripferon as an effective means of prevention and treatment of influenza”. Infectious Diseases 1 (2003): 70-74.
24. Barnett JM., et al. “Zanamivir susceptibility. Monitoring and characterization of influenza virus. Clinical izolates obteined during phase. clinical effucacy studies”. Antimicrobial Agents and Chemotherapy 44 (2000): 78-87.
25. Leneva IA and Shuster AN. “Antiviral etiotropic chemotherapeutics: effectiveness against influenza A subtype H5N1”. Vopr Virusol 5 (2006): 4-7.
26. Mishin Vasiliy P., et al. “Sensitivity of influenza viruses resistant to antiviral drugs, to new neuraminidase (NA) inhibitors”. Antimicrobial Agents and Chemotherapy11 (2005): 4515-4520.
27. Divocha VA. “Inhibitor of trypsin-like proteases as an antiviral agent”. Patent of Ukraine № 37324А dated 15.05.2001. 4.7 (2001).
28. Divocha VA., et al. “Antiviral action of a cellular inhibitor”. Homeostasis and infectious process. Saratov (1996): 8.

Citation

Citation: Valentina Divocha. “Traditional and Prospective Approaches to Influence Prevention”. Acta Scientific Microbiology 4.11 (2021): 11-15.

Copyright

Copyright: © 2021 Valentina Divocha. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.